{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bronchiectasis/prescribing-information/flucloxacillin/","result":{"pageContext":{"chapter":{"id":"cf1fbf18-e60a-54f7-bbc4-2a30ab37f565","slug":"flucloxacillin","fullItemName":"Flucloxacillin","depth":2,"htmlHeader":"<!-- begin field 5cda403a-2daf-490e-a4de-ac0d010a86fc --><h2>Flucloxacillin</h2><!-- end field 5cda403a-2daf-490e-a4de-ac0d010a86fc -->","summary":"","htmlStringContent":"<!-- begin item c722eb8b-2d51-42cb-89a4-75e9d34e71b4 --><!-- end item c722eb8b-2d51-42cb-89a4-75e9d34e71b4 -->","topic":{"id":"96a8622b-46f5-55fa-b729-6748e3d98c98","topicId":"26fab339-e333-44ec-a481-de87a29052f3","topicName":"Bronchiectasis","slug":"bronchiectasis","lastRevised":"Last revised in January 2021","chapters":[{"id":"43d88c30-f768-5e1c-a6ea-5596c5577fb5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ac4fde9a-5fd3-5ed9-9201-f714bda470bb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0b34af83-d49a-5145-8589-e8748b8646c0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"04eeb1ae-4fc3-5418-83a2-b62587d8bdda","slug":"changes","fullItemName":"Changes"},{"id":"dbd8ad5a-871c-59b8-9729-444e11ac9df1","slug":"update","fullItemName":"Update"}]},{"id":"b89644c6-805f-50b4-991d-36bb2b0fbf67","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d38de329-73b8-5fed-83ef-f836b765cd3f","slug":"goals","fullItemName":"Goals"},{"id":"3c116665-5586-5551-909c-0efc1ef0be62","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"60e13bc0-e351-5c39-b8ff-9a8d4514bf16","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2ee37cc0-9ff4-5bbd-ab3f-0a30cb904bb5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d155aa4f-7dfe-575d-a7dd-a87774f4cbad","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"07c3e24b-c950-516e-9070-5441a07b3791","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5146c866-f0a7-54a6-a5ac-8aff4b385cc6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e2107a7e-b7c3-5ba9-94e4-6217ea79a3f2","slug":"definition","fullItemName":"Definition"},{"id":"39df7c47-de08-57ae-aa40-89a7d4d7b031","slug":"causes","fullItemName":"Causes"},{"id":"ac4d346e-97d4-5d84-a704-fbdcf56be7f4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e07a8b0b-866c-5789-85ef-020a5b19b620","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"ef5c5e7b-3cf4-5939-85e0-b61cae41f945","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ce267b5b-70dd-52bd-ad83-6123bd42fa0d","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c605c0b9-0519-50e1-abd8-2dc47de7278a","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"23a1627d-30f7-5ba4-95f8-060faf797f51","slug":"suspected-infective-exacerbation-diagnosis","fullItemName":"Suspected infective exacerbation diagnosis"}]},{"id":"5a5846fa-c8b4-5cd4-b2d3-770c3dc00ba2","fullItemName":"Management","slug":"management","subChapters":[{"id":"0180d43c-dd8d-5a87-915c-629542f782fe","slug":"suspected-bronchiectasis","fullItemName":"Scenario: Suspected bronchiectasis"},{"id":"290c51ae-6521-5c03-b12e-117e40c88883","slug":"infective-exacerbation","fullItemName":"Scenario: Infective exacerbation"},{"id":"1e90ec28-8eea-5ab7-ac76-2df1ace279de","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ba1a593e-f80b-5c5f-be50-5979b491bc70","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6db0266e-4d15-5eec-b2c0-ed20f472eeb5","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"a98b5813-5589-5247-9c65-e9ae534d88c2","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"04c99c8f-7a1d-55f0-85a2-6d0e1bc3e4e3","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"26b521e3-9c5e-5a7c-956b-7f3f39f2e58c","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"6cd6079a-be84-5279-9d10-e3bf4653c049","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"8ed4a900-3e69-51c0-8cd5-c2b0bee9bfe2","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"5217d027-064d-5543-93b0-7e8bb1a1c0fc","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"cf1fbf18-e60a-54f7-bbc4-2a30ab37f565","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"8e888abe-cb05-5343-b6e3-547dea7312cc","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"}]},{"id":"118b4e08-e6ae-510a-b2f5-51b109ef3395","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ecf8de37-d8f0-5ced-af38-9be20fa73de9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1c227675-02ea-5c9e-a927-e385987adf53","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f74bbe64-1998-528f-b811-df2a14219de7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2a925d45-6865-5cd5-9624-23da53ee221a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a6ff3076-9be6-55b4-b373-f40cb3045f2c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67608f46-5eba-58f9-86e3-0e0e3f57d921","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3fae7f8d-20fb-5fe6-af57-64882afceb3a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ba1a593e-f80b-5c5f-be50-5979b491bc70","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"70065cd7-faf3-5113-85d5-15923e51d5e0","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field d354ceca-3c3b-4d5a-9380-ac0d010a86fc --><h3>What contraindications and cautions are associated with flucloxacillin?</h3><!-- end field d354ceca-3c3b-4d5a-9380-ac0d010a86fc -->","summary":null,"htmlStringContent":"<!-- begin item 3e41fac6-23c0-4951-b201-4e0915e9e284 --><!-- begin field 3f40c2eb-4bd4-4685-8cb5-ac0d010a86fc --><ul><li><strong>Do not prescribe flucloxacillin in people with:</strong><ul><li>A true penicillin allergy — allergic reactions to penicillins occur in 1–10% of exposed individuals; anaphylactic reactions occur in fewer than 0.05% of treated patients.<ul><li>Gastrointestinal adverse effects alone (for example nausea, vomiting, or diarrhoea) do not constitute an allergy to penicillin.</li></ul></li><li>History of flucloxacillin-associated jaundice or hepatic dysfunction.</li></ul></li><li><strong>Prescribe flucloxacillin with caution in people with:</strong><ul><li>Hepatic dysfunction (not flucloxacillin-related), especially if they are 50 years of age or older, or have a serious underlying medical condition.</li><li>Severe renal impairment — reduce the dose if the person's estimated glomerular filtration rate (eGFR) is less than 10 mL/minute/1.73 m<sup>2</sup>.</li><li>A history of allergy — these people are more likely to develop a sensitivity reaction.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 3f40c2eb-4bd4-4685-8cb5-ac0d010a86fc --><!-- end item 3e41fac6-23c0-4951-b201-4e0915e9e284 -->","subChapters":[]},{"id":"010b9f96-02d8-546a-9918-d2ac86e1d5b5","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field adf6f928-5ae8-4bbc-85fa-ac0d010a86fc --><h3>What are the adverse effects of flucloxacillin?</h3><!-- end field adf6f928-5ae8-4bbc-85fa-ac0d010a86fc -->","summary":null,"htmlStringContent":"<!-- begin item cf5574f0-6d8a-45ab-bd6d-0c608f5f5ed5 --><!-- begin field 51d1ff24-c12b-4a82-93ec-ac0d010a86fc --><ul><li><strong>Gastrointestinal </strong>— nausea and vomiting (common).<ul><li><strong>Very rarely: </strong>antibiotic-associated colitis.</li></ul></li><li><strong>Nervous system</strong> — headache, dizziness (uncommon).</li><li><strong>Skin</strong> <strong>and subcutaneous tissue</strong> — skin rash, urticaria, purpura (uncommon).<ul><li><strong>Very rarely:</strong> erythema multiforme, Stevens–Johnson syndrome, toxic epidermal necrolysis, generalized exanthematous pustulosis.</li></ul></li><li><strong>Other rare, or very rare adverse effects include:</strong><ul><li>Anaphylaxis.</li><li>Arthralgia and myalgia (very rare).</li><li>Hepatitis, cholestatic jaundice — this may occur up to several weeks after treatment with flucloxacillin has been stopped. Risk factors include treatment for more than 2 weeks, and increasing age.</li><li>Interstitial nephritis.</li><li>Neutropenia, thrombocytopenia, haemolytic anaemia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 51d1ff24-c12b-4a82-93ec-ac0d010a86fc --><!-- end item cf5574f0-6d8a-45ab-bd6d-0c608f5f5ed5 -->","subChapters":[]},{"id":"d44587bf-1e4a-5f38-9e46-c83ce01a8fd6","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field c4549b28-cc20-4d9a-bfaa-ac0d010a86fc --><h3>What drug interactions are important for flucloxacillin?</h3><!-- end field c4549b28-cc20-4d9a-bfaa-ac0d010a86fc -->","summary":null,"htmlStringContent":"<!-- begin item d9a0eed7-ba9d-4f80-b007-eb2ed8ae4772 --><!-- begin field 83745390-0853-440e-880b-ac0d010a86fc --><ul><li><strong>Methotrexate </strong>— flucloxacillin may reduce methotrexate clearance, causing an increased risk of toxicity.<ul><li>For people on high dose methotrexate, routine monitoring will identify any decreases in elimination. For people, on low dose methotrexate, consult local or national guidelines/protocols for recommendations on monitoring and management. </li></ul></li><li><strong>Oral anticoagulants</strong> (warfarin, phenidione) — consider monitoring the international normalized ratio (INR) within 3 days of starting or stopping a penicillin and adjust the dose accordingly.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of flucloxacillin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Typhoid vaccine</strong> — antibacterials might reduce the immune response. The World Health Organization (WHO) recommends that the antibacterial is stopped from 3 days before to 3 days after receiving live oral typhoid vaccine.</li></ul><!-- end field 83745390-0853-440e-880b-ac0d010a86fc --><!-- end item d9a0eed7-ba9d-4f80-b007-eb2ed8ae4772 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}